NaNots for Astronauts!
MILL VALLEY, CA., September 24th, 2024 – NaNotics LLC, a biopharmaceutical company developing NaNots® – novel subtractive nanoparticles that treat disease by capturing and clearing pathogenic molecules from blood – today announced that it has been selected for the inaugural SPACE-H Accelerator program – a collaboration between Starburst, NASA’s Human Research Program, the Translational Research Institute for Space Health, Methuselah Foundation, and Microsoft Federal. The SPACE-H mission is “to support entrepreneurs working to advance biological and medical capabilities with the potential to minimize the health and performance risks in human spaceflight.” Read the announcement here: https://bit.ly/47Ag2It
Space is a harsh and inhospitable environment for humans, posing unique health challenges for crew and passengers. Environmental factors can accelerate aging and give rise to various diseases. Treatment options are limited by the size, weight and training required to operate medical technology commonly used on Earth. Multiple space exploration programs – including Artemis, which seeks to establish a permanent lunar base – are now creating opportunities to advance biological research and support development of next generation, autonomous systems for maintaining astronaut health on long duration spaceflights.
“Space-H has been set up specifically to accelerate advanced health systems to support space exploration,” said Starburst’s USA Managing Director, Elizabeth Reynolds. “We selected NaNotics LLC for our inaugural program because NaNots® – a highly novel therapeutic platform – have the potential to address significant medical challenges associated with deep space travel.”
NaNots are a new class of medicine for treating cancer and inflammatory diseases, by adsorbing specific molecules from blood that drive or enable these diseases. For instance, profound tumor suppression can be achieved via adsorption of tumor-generated immune inhibitors, as reported by Mayo Clinic, which tested NaNots in a humanized mouse model of triple negative breast cancer – which responds poorly to conventional drugs. Deadly “cytokine storms” can also be extinguished with NaNots that rapidly adsorb the inflammatory molecules that drive these storms. NaNots are especially well-suited for use in deep space because they can be administered by simple injection.
“We’re very excited to have been selected for the first cohort of the SPACE-H program,” said Lou Hawthorne, CEO of NaNotics and the inventor of NaNots®. “The SPACE-H program is run by some of the world’s top technologists; their interest in our work speaks to the advanced nature of the NaNot platform and its potential significance for maintaining health in space as well as on Earth.”
For more information on NaNots and potential use in space, download the company white paper – “NaNots for Astronauts”: https://bit.ly/47qu2V8
#space #medicine #innovation #future #longevity